State of Hypertension Management in the United States: Confluence of Risk Factors and the Prevalence of Resistant Hypertension

被引:89
作者
Sarafidis, Pantelis A. [2 ]
Bakris, George L. [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Hypertens Dis Unit, Dept Med,Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA
[2] Aristotle Univ Thessaloniki, AHEPA Hosp, Dept Med 1, Sect Nephrol & Hypertens, Thessaloniki, Greece
关键词
D O I
10.1111/j.1751-7176.2008.07309.x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
An improvement in the awareness and treatment of hypertension in the United States has occurred, resulting in the best control rates in the world, which unfortunately are far below the goals of Healthy People 2000 or 2010. This failure to achieve blood pressure (BP) goals is attributed to many factors, including an aging population, higher prevalence of kidney disease and obesity, high salt intake, physician inertia to increase dose and number of antihypertensive medications prescribed, and patient nonadherence with medication regimens. Resistant hypertension is defined as a failure to achieve goal BP in patients who adhere to full doses of an appropriate antihypertensive regimen of 3 drugs that includes a diuretic. The problem of resistant hypertension is projected to increase as the population ages. Efforts on the part of the Veterans Administration hospitals and others clearly indicate that a system can be implemented to help increase the percentage of persons in whom BP goal is achieved and reduce the prevalence of resistant hypertension. Medications specific to the problem of resistant hypertension are also under development. This review analyzes the status of hypertension control in the United States, the frequency of associated diseases, and adherence to guidelines; it further discusses strategies to reduce the prevalence of resistant hypertension. (J Clin Hypertens (Greenwich). 2008;10:130-139) (C) 2008 Le Jacq
引用
收藏
页码:130 / 139
页数:10
相关论文
共 61 条
[1]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[2]  
Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1
[3]  
[Anonymous], 2005, AM J MANAG CARE, V11, pS383
[4]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[5]  
Bakris George L, 2003, J Clin Hypertens (Greenwich), V5, P202, DOI 10.1111/j.1524-6175.2002.2041.x
[6]   Differential effects of β-blockers on albuminuria in patients with type 2 diabetes [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
Mcgill, JB ;
Messerli, F ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Waterhouse, B ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
HYPERTENSION, 2005, 46 (06) :1309-1315
[7]   Effects of blood pressure level on progression of diabetic nephropathy - Results from the RENAAL study [J].
Bakris, GL ;
Weir, MR ;
Shanifar, S ;
Zhang, ZX ;
Douglas, J ;
van Dijk, DJ ;
Brenner, BM .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (13) :1555-1565
[8]   General characteristics of the insulin resistance syndrome - Prevalence and heritability [J].
Beck-Nielsen, H .
DRUGS, 1999, 58 (Suppl 1) :7-10
[9]   Is resistant hypertension really resistant? [J].
Brown, MA ;
Buddle, ML ;
Martin, A .
AMERICAN JOURNAL OF HYPERTENSION, 2001, 14 (12) :1263-1269
[10]   TRENDS IN THE PREVALENCE, AWARENESS, TREATMENT, AND CONTROL OF HYPERTENSION IN THE ADULT US POPULATION - DATA FROM THE HEALTH EXAMINATION SURVEYS, 1960 TO 1991 [J].
BURT, VL ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D ;
WHELTON, P ;
BROWN, C ;
ROCCELLA, EJ .
HYPERTENSION, 1995, 26 (01) :60-69